Pharmacogenetic Study of the medication Ondansetron in Alcohol Use Disorder

Brief Description Of Study

The primary study objective is to determine the efficacy of ondansetron (0.33 mg twice daily) administered orally for a period of 16 weeks in reducing risky drinking among currently drinking African American subjects with Alcohol Use Disorder who have selected genotypes at the serotonin transporter and receptor genes. The secondary objective is to assess the safety and tolerability of ondansetron in subjects with alcohol use disorder who have selected genotypes at the serotonin transporter and receptor genes. The study will last approximately 20 weeks including a screening visit, 11 regular study visits, and a follow-up visit.

Clinical Study Identifier: TX1088

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: Pharmacogenetic Study of the medication Ondansetron in Alcohol Use Disorder
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.